Alume Biosciences, Inc., has revealed the first patient has been dosed a in Phase 3 Pivotal Study of ALM-488 (NCT05377554) in patients undergoing head and neck surgery.
ALM-488 is a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery.
Alume Biosciences chief medical officer Brett Berman MD said: "The successful initiation of this Phase 3 pivotal study is another major milestone for Alume.
“It marks the final phase of clinical trial testing for ALM-488 for patients undergoing Head and Neck Surgery.
This study underscores our commitment to improve intraoperative visualization of nerves, enabling Precision Surgery.
For further information about Alume Biosciences visit https://alumebiosciences.com
